A Phase 1 interventional study of Autologous Adult Stem Cell-Derived Intestinal Organoid in Crohn's Diseases and Crohn's Disease, sponsored by ORGANOIDSCIENCES LTD.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by ORGANOIDSCIENCES LTD. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 117 studies in Crohn Disease with a site in Korea, Republic of — 31 open to participants now, 41 under way, 26 of them phase 3. Crohn Disease · Korea, Republic of.
Among the 117 studies in Crohn Disease with a site in Korea, Republic of, this one is the 90th largest by planned enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 1, reaches primary completion later than 24 of the 40 other live ones, and was the 117th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →31 of the 117 studies in Crohn Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Korea, Republic of, United States, Argentina and 27 more countries
Ages 18+
Sanofi · Sites in Korea, Republic of, United States, Australia and 24 more countries
Ages 16–80
Takeda · Sites in Korea, Republic of, United States, Belgium and 11 more countries
Ages 2–17
Janssen Research & Development, LLC · Sites in Korea, Republic of, United States, Argentina and 25 more countries
Ages 18+
Sanofi · Sites in Korea, Republic of, United States, Argentina and 33 more countries
Ages 16–80
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 19 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
117 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 27 · Phase 3 63 · Phase 4 6
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 280 across the 95 interventional studies, 341 across the 22 observational. Of the 67 that completed or were terminated, 50 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
96 of 117 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with ORGANOIDSCIENCES LTD. as lead sponsor.
ORGANOIDSCIENCES LTD. has 1 study filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
11 of the studies in Crohn Disease with a site in Korea, Republic of that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
Add all 11 to your calendar (.ics) → With an account.
Among the 117 studies in Crohn Disease with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 1 study evaluates the safety and tolerability of ATORM-C in patients with Crohn's disease. ATORM-C is an investigational product consisting of autologous adult stem cell-derived intestinal organoids. Participants will receive a single dose of ATORM-C applied directly to a target intestinal ulcer during colonoscopy. The study will also explore the effect of ATORM-C on intestinal ulcer healing.
This is an open-label, sequential dose-escalation Phase 1 study to evaluate the safety, tolerability, and exploratory efficacy of ATORM-C across three dose levels in patients with Crohn's disease. ATORM-C is manufactured by culturing and expanding autologous adult stem cell-derived intestinal organoids isolated from each participant's intestinal tissue. Participants will receive a single administration of ATORM-C directly applied to a target intestinal ulcer during colonoscopy. Primary evaluations will focus on safety and tolerability, with exploratory assessments of ATORM-C's effect on intestinal ulcer healing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet all of the following colonoscopy findings at screening:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
16,330 organoids (0.2 mL) per cm² of ulcer area
Biological: Autologous Adult Stem Cell-Derived Intestinal Organoid
81,650 organoids (0.2 mL) per cm² of ulcer area
Biological: Autologous Adult Stem Cell-Derived Intestinal Organoid
163,300 organoids (0.2 mL) per cm² of ulcer area
Biological: Autologous Adult Stem Cell-Derived Intestinal Organoid
ATORM-C is an investigational product consisting of autologous adult stem cell-derived intestinal organoids. Participants will receive a single administration of ATORM-C applied directly to the target intestinal ulcer during colonoscopy. ATORM-C is administered with fibrin glue (Greenplast-Q) to facilitate local application to the target ulcer.
Dose-Limiting Toxicities (DLTs)
Occurrence of dose-limiting toxicities (DLTs). A DLT is defined as any Grade 3 or higher adverse reaction according to NCI CTCAE v5.0 that is assessed as possibly, probably, or certainly related to ATORM-C. CTCAE grades range from Grade 1 (mild) to Grade 5 (death related to an adverse event), with higher grades indicating greater severity.
Time frame: From ATORM-C administration through 4 weeks post-dose
Determination of Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
The MTD and RP2D of ATORM-C will be determined based on the occurrence of dose-limiting toxicities (DLTs) during the dose-escalation period and the overall safety and tolerability of ATORM-C.
Time frame: From ATORM-C administration through 24 weeks post-dose
Incidence of Adverse Events (AEs) and Adverse Events of Special Interest (AESIs)
Occurrence of treatment-emergent adverse events (TEAEs), adverse drug reactions (ADRs), serious adverse events (SAEs), serious adverse drug reactions (SADRs), adverse events of special interest (AESIs), and administration site local adverse events. Adverse events leading to discontinuation of study treatment or death will also be evaluated.
Time frame: From ATORM-C administration through 24 weeks post-dose
Changes in Clinical Laboratory Tests, Vital Signs, Physical Examinations, and 12-Lead Electrocardiograms (ECGs)
Changes from baseline in continuous safety parameters, including clinical laboratory tests and vital signs, evaluated at protocol-specified visits. Occurrence of clinically significant abnormalities (Abnormal CS) in clinical laboratory tests, physical examinations, and 12-lead electrocardiograms (ECGs) post-dose will also be evaluated.
Time frame: Baseline through 24 weeks post-dose, at protocol-specified visits
Change from Baseline in Target Ulcer Size
Absolute change and percentage change from baseline in the size of the target ulcer, evaluated based on the longest diameter, shortest diameter, and total surface area measured during colonoscopy at protocol-specified time points.
Time frame: Baseline and Weeks 4, 12, and 24 post-dose
Change from Baseline in Modified Global Histologic Disease Activity Score (Modified GHAS) of the Target Ulcer
Change from baseline in the Modified Global Histologic Disease Activity Score (Modified GHAS) based on histologic evaluation of mucosal biopsy specimens collected from the target ulcer. The regional Modified GHAS ranges from 0 to 12, with higher scores indicating greater histologic disease activity.
Time frame: Baseline and Week 24 post-dose
Change from Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) of the Target Ulcer
Change from baseline in the Simple Endoscopic Score for Crohn's Disease (SES-CD) total score and ulcer size subscore evaluated specifically for the target ulcer via colonoscopy. The SES-CD assessed for the target ulcer evaluates 4 endoscopic variables, each scored from 0 to 3, yielding a target ulcer regional score ranging from 0 to 12. Higher scores indicate greater endoscopic disease activity.
Time frame: Baseline and Weeks 4, 12, and 24 post-dose
Proportion of Participants Achieving ≥50% Reduction from Baseline in SES-CD Score of the Target Ulcer
Percentage of participants who achieve a 50% or greater reduction from baseline in the Simple Endoscopic Score for Crohn's Disease (SES-CD) total score for the target ulcer at Week 24 post-dose. The regional target ulcer SES-CD ranges from 0 to 12, with higher scores indicating greater endoscopic disease activity.
Time frame: Baseline and Week 24 post-dose
Proportion of Participants Achieving Endoscopic Remission of the Target Ulcer
Percentage of participants achieving endoscopic remission of the target ulcer at Week 24 post-dose. Endoscopic remission is defined as a Simple Endoscopic Score for Crohn's Disease (SES-CD) total score of less than 2 (\<2) for the target ulcer. The regional target ulcer SES-CD ranges from 0 to 12, with higher scores indicating greater endoscopic disease activity.
Time frame: Baseline and Weeks 4, 12, and 24 post-dose
Proportion of Participants Achieving a ≥100-Point Reduction from Baseline in Crohn's Disease Activity Index (CDAI)
Percentage of participants who achieve a reduction of 100 points or greater (≥100 points) from baseline in the Crohn's Disease Activity Index (CDAI) total score at Week 24 post-dose. CDAI total scores range from 0 to over 600, with higher scores indicating greater disease activity. Frequencies and percentages will be summarized for each dose cohort and overall.
Time frame: Baseline and Week 24 post-dose
Proportion of Participants Achieving Clinical Remission Based on Crohn's Disease Activity Index (CDAI)
Percentage of participants who achieve clinical remission, defined as a Crohn's Disease Activity Index (CDAI) total score of less than 150 (\<150) at protocol-specified time points post-dose. Higher CDAI scores indicate greater Crohn's disease activity.
Time frame: Weeks 4, 12, and 24 post-dose
Proportion of Participants Achieving Clinical Response Based on Patient-Reported Outcomes (PRO2)
Percentage of participants who achieve a clinical response based on patient-reported outcomes (PRO2), defined as a reduction of 30% or greater (≥30%) from baseline in either the 7-day average Stool Frequency (SF) subscore or Abdominal Pain (AP) subscore, with neither subscore worsening from baseline. The SF subscore ranges from 0 to 11+ (higher scores reflect greater stool frequency), and the AP subscore ranges from 0 to 3 (higher scores indicate more severe pain).
Time frame: Baseline, and Weeks 4, 12, and 24 post-dose
Proportion of Participants Achieving Clinical Remission Based on Patient-Reported Outcomes (PRO), Defined as SF ≤2.8 and AP ≤1.0
Percentage of participants who achieve clinical remission based on patient-reported outcomes (PRO2), defined as a 7-day average daily Stool Frequency (SF) of 2.8 or less (≤2.8) and a 7-day average Abdominal Pain (AP) score of 1.0 or less (≤1.0). Higher SF values indicate greater stool frequency, and higher AP scores indicate more severe abdominal pain.
Time frame: Weeks 4, 12, and 24 post-dose
Change and Percentage Change from Baseline in Fecal Calprotectin Levels
Absolute change and percentage change from baseline in fecal calprotectin levels (measured in µg/g) at protocol-specified time points post-dose.
Time frame: Baseline, and Weeks 4, 12, and 24 post-dose
Change and Percentage Change from Baseline in C-Reactive Protein (CRP) Levels
Absolute change and percentage change from baseline in C-reactive protein (CRP) levels (measured in mg/L) at protocol-specified time points post-dose.
Time frame: Baseline, and Weeks 4, 12, and 24 post-dose
Use of Rescue Medication During the Study
Percentage of participants who use rescue medication and the amount of rescue medication used at protocol-specified visits during the study period.
Time frame: From ATORM-C administration through 24 weeks post-dose
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Aug 2028, 23 months later.
Of 33 industry-sponsored phase 1 interventional studies under Crohn Disease, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 23 months is above that.
Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.